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ABSTRACT 
Whilst previous research has indicated an association between osteoarthritis and cardiovascular 
disease, it remains unclear whether people with osteoarthritis are at greater risk of developing 
hypertension. The aim of this study was to answer this uncertainity. We used the data of the 
Osteoarhritis Iniative, an ongoing public and private longitudinal study including people at higher 
risk of osteoarthritis or having knee osteoarthritis. Knee osteoarthritis was defined through 
radiological and clinical assessment. Incident hypertension was defined as a systolic blood pressure 
>140 mmHg and/or a diastolic value >90 mmHg. Multivariate Cox’s regression analyses were 
constructed where the presence of knee osteoarthritis as the exposure and incident hypertension as 
the outcome during a 96 month follow-up interval.  A total of  3,558 people with normative blood 
pressure values at baseline were analyzed (1,930 OA / 1,628 controls). Incidence of hypertension 
within the follow-up interval was significantly higher in people with knee osteoarthritis compared to 
those without (60/ vs. 55/1,000 persons/years; p<0.0001). After adjusting for 13 confounders, people 
with knee osteoarthritis had a 13% higher chance of developing hypertension (Hazard ratio = 1.13; 
95%CI: 1.01-1.26, p=0.03). Propensity score analysis did not alter these conclusions. In conclusion, 
this is the first longitudinal data analysis to demonstrate that people with knee osteoarthritis have a 
higher chance of developing hypertension compared to those without osteoarthritis. Our data suggests 
that monitoring blood pressure and prescribing health promotion interventions may be warranted 
among people with osteoarthritis to mitigate the potential onset and adverse consequences of 
hypertension.  
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INTRODUCTION 
Osteoarthritis is one of the most common chronic musculoskeletal diseases worldwide. [1,2] It has a 
high prevalence, estimated to be 10% in men and 20% in women over the age of 60 years. [3] Previous 
research has demonstrated that people with osteoarthritis have a higher prevalence of cardiovascular 
diseases (CVD), as reported by a recent meta-analysis including more than one million participants. 
[4]   People with osteoarthritis have a number of risk factors for CVD, such as low levels of physical 
activity, [5] high levels of depressive and anxiety symptoms, [6] and metabolic abnormalities, such 
as diabetes and metabolic syndrome. [7]  Whilst cross-sectional data suggests increased prevalence 
of CVD in those with osteoarthritis, [4] considerably less is known about the incidence of CVD. Some 
recent studies have suggested that people with osteoarthritis may be at increased risk of developing 
CVD, although with no univocal results. [8–10]  This is concerning since CVD is a leading cause of 
global mortality, particularly in the Western world. [11] Furthermore people with osteoarthritis may 
be at increased risk of premature death due to CVD. [12]   
 
The heightened risk of CVD among people with osteoarthrits has been hypothesized to be increased 
and potentially influenced through various mechanisms. Firstly, osteoarthritis is often characterized 
by some degree of low-grade inflammation which is also a potential CVD risk factor. [13] Secondly, 
osteoarthritis is characterized by relevant modifications of extra-cellular matrix (ECM) [14] which 
may also increase the risk of CVD. [15] Finally, pain and disability associated with osteoarthritis may 
result in physical inactivity, which, over time, may subsequently led to CVD. [16]  
 
Whilst a significant number of cross-sectional studies have reported the association between 
osteoarthritis and hypertension [17–24], no longitudinal studies have to the best of our knowledge 
examined the incidence of hypertension in this population. This is an important omission given that 
it remains unclear whether there is a causal relationship between osteoarthritis and hypertension 
which may provide further insights into its pathophysiology for those with osteoarthritis. Whilst 
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longitudinal research cannot infer causality, it can enable some clarification of the directionality of 
the cross-sectional relationships observed. Moreover, such analyses would also provide greater 
insight into the magnitude of this comorbidity within this population, which has clinical relevance for 
preventing the sequalae of hypertension such as stroke and CVD. [25] It may also identify appropriate 
targeted interventions to prevent hypertension in people with osteoarthritis if a relationship were 
observed.   
 
Given this, the purpose of this study was to determine whether people with knee osteoarthritis have 
an increased chance of developing hypertension over an eight-year follow-up period, compared to 
people without knee osteoarthritis.  
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METHODS 
Data source and subjects 
All participants in this study were recruited as part of the ongoing, publicly and privately-funded, 
multicenter Osteoarthritis Initiative (OAI) study, which is available for public access 
(http://www.oai.ucsf.edu/). Patients were recruited from four clinical sites in the US (Baltimore, MD; 
Pittsburgh, PA; Pawtucket, RI; and Columbus, OH) between February 2004 and May 2006.  
 
The OAI study protocol was approved by the institutional review board of the OAI Coordinating 
Center, University of California at San Francisco. Specific datasets used were those recorded during 
baseline and screening evaluations (November 2008) and those evaluating the participants until the 
last evaluation (after 96 months from baseline evaluation). 
 
Cases 
The osteoarthritis cohort was the ‘cases’ and were defined as: i) having knee osteoarthritis and 
reported knee pain in a 30-day period in the past 12 months; or ii) at high risk of developing knee 
osteoarthritis at baseline (e.g. overweight/obese, knee injury/operation, parents/siblings with total 
knee replacement, frequent knee-bending activities that increase risk, and hand/hip osteoarthritis). 
All participants provided written informed consent. Knee osteoarthritis was defined as the 
combination in the clinical reporting and assessment of pain and stiffness (i.e. pain, aching or stiffness 
in or around the knee on most days during the last year), and radiographical evidence of osteoarthritis 
on the baseline fixed-flexion radiograph defined as the presence of tibiofemoral osteophytes 
(correspondent to Osteoarthritis Research Society International atlas grades 1-3, clinical center 
reading; [26]).  In the OAI, the presence of pain, stiffness, and physical functioning (or disability) 
due to OA was assessed through the WOMAC (Western Ontario and McMaster Universities Arthritis 
Index).[27] Briefly, the responses for each subscale (pain, stiffness, disability) are categorized on a 
five-point Likert scale ranging from none (0 points) to extreme (4 points). The maximum possible 
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score is 68, and the final score was normalized to 100 (range 0–100), with higher scores reflecting 
greater activity limitations. [27] 
 
Outcomes 
The assessment of blood pressure was made through a single measurement performed by a trained 
nurse at the right arm, unless contraindicated. Hypertension was defined as a value of systolic blood 
pressure > 140 and/or diastolic blood pressure > 90 mmHg in agreement with the guidelines 
suggested for this condition. [28] In the OAI dataset, blood pressure was recorded at baseline and 
follow-up points of 12, 24, 36, 48, 72 and 96 months. Incident hypertension was defined as a 
normal blood pressure measurement at baseline but a measurement reaching the hypertensive 
threshold within a subsequent follow-up interval. 
 
Covariates 
Several candidate explanatory variables were identified to explore the possible association between 
osteoarthritis and incident hypertension. These included: race (“whites” vs. others); smoking habits 
(“previous/current” vs. never); educational level (“degree” vs. others); yearly income (missing data, 
< or > $50,000); body mass index (BMI) measured by a trained nurse with a cut-off of more/equal 
than 30 Kg/m2 for defining obesity; and medical co-morbidities were assessed through the modified 
Charlson Comorbidity Index (CCI), where higher scores indicate an greater number of morbidities 
and poorer health [29]; physical activity was evaluated through the validated Physical Activity Scale 
for the Elderly [30]. The scale covers 12 different activities, such as walking, sports, and housework, 
and is scored from 0 without a maximum score; and any depressive symptoms was derived from the 
20-item Center for Epidemiologic Studies-Depression (CES-D) instrument [31]. The range of possible 
values for scale scores is 0–60, with the higher scores indicating more depressive symptoms [31]. 
Specifically the diagnosis of diabetes, chronic obstructive pulmonary disease (COPD), cancer or 
cardiovascular disease (i.e. the presence of heart failure, heart attack, peripheral artery disease, and/ 
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or stroke) were reported descriptvetly in our analyses. Finally, also the use of non-steroidal anti-
inflammatory drugs (NSAIDs) (prescribed or not by a doctor) was included as potential confounder.  
 
Statistical analyses 
For continuous variables, data normality was assessed and confirmed using the Kolmogorov-Smirnov 
test. Data were presented as mean and standard deviation (SD) values for quantitative measures, and 
frequency and percentages for discrete variables by knee osteoarthritis presence. P-values were 
calculated for continuous variables using the independent Student T-test and for categorical 
parameters the chi-square test between people with knee osteoarthritis compared to those without.  
 
The incidence of cases who developed hypertension within the follow-up period was calculated as 
the number of new cases per 1000 person-years during the follow-up. Multivariate Cox’s regression 
analyses were constructed using the presence of knee osteoarthritis as the exposure and incident 
hypertension during the follow-up period as the outcome. The multivariate model included all 
confounding factors that were significantly different between participants with and without knee 
osteoarthritis at baseline or were significantly associated with incident hypertension at follow-up 
(denoted as p-value <0.05 for both selections). Multi-collinearity among covariates was assessed 
through variance inflation factor (VIF), taking a cut-off of two as reason for exclusion. No variable 
was excluded for this reason. The basic model was not adjusted for any confounders, whilst the fully 
adjusted model adjusted for baseline values of: age; gender; race; BMI; education; smoking habits; 
yearly income; CCI; baseline PASE score; baseline CESD score; use of NSAIDs; and baseline values 
of systolic and diastolic BP. In a sensitivity analysis, to better control the role of possible confounding 
effects on the association between knee osteoarthritis and incident hypertension, the propensity score 
matching methodology was applied.[32] Data of Cox’s regression analyses were reported as hazard 
ratios (HRs) with 95% confidence intervals (CIs).  
 
9 
 
Several sensitivity analyses were conducted evaluating the interaction between the presence of knee 
osteoarthritis and selected factors (e.g. age below or more than 65 years, obesity, presence of any 
disease, yearly income, gender, race, education, smoking habits, yearly income and presence/absence 
of diabetes and CVD at baseline) in predicting hypertension at follow-up, although no factor was 
significant.  
 
All analyses were performed using the SPSS 21.0 for Windows (SPSS Inc., Chicago, Illinois). All 
statistical tests were two-tailed and statistical significance was assumed for a p-value <0.05. 
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RESULTS 
Study participants 
Among 4,796 potentially eligible individuals, 1,005 were excluded due to pre-existing hypertension 
at the baseline assessment, 33 were excluded as there was insufficient information to confirm a 
diagnosis of knee osteoarthritis and 200 were lost at follow-up. Accordingly, 3,558 participants were 
eligible for this study (Figure 1).   
 
Baseline analyses  
The 3,558 participants (1,439 males/2,119 females) had a mean age of 60.4±9.0 years (range: 45-79). 
At baseline, 1,930 people with knee osteoarthritis were compared to 1,628 participants without knee 
osteoarthritis.   
 
The baseline characteristics of the knee osteoarthritis and non-osteoarthritis participants (i.e. 
participants at higher risk of knee osteoarthritis) are reported in Table 1. The osteoarthritis 
participants were more frequently older (61.8±9.1 versus 58.9±8.8 years) than those without 
osteoarthritis (p<0.0001), whilst no significant differences emerged in terms of gender and race. 
Individuals with knee osteoarthritis had significantly higher BMI values, had a higher educational 
level and income, and they were less active compared to the non-osteoarthritis group (Table 1).  
Regarding medical conditions, participants with osteoarthritis more frequently reported diabetes and 
had a higher CCI (Table 1). Finally, participants with knee osteoarthritis showed significantly higher 
systolic blood pressure (119.4±10.8 versus 117.1±11.3 mmHg, p<0.0001) and diastolic blood 
pressure (73.4±8.1 versus 72.7±8.6 mmHg, p=0.02) values at baseline compared to without 
osteoarthritis. No significant differences emerged in terms of the use of NSAIDs between individuals 
with knee OA and the controls (p=0.06).  
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Follow-up analyses  
After a 96 month follow-up, 1,428 individuals (40.2% of the baseline population) developed 
hypertension, with an incidence of 57 cases (95% CI: 23-85) per 1,000 person-years. The incidence 
of newly diagnosed hypertension was significantly higher in people with knee osteoarthritis at 
baseline (60 per 1,000 person-years; 95% CI: 37 to 85) compared to those without (55 per 1,000 
person-years; 95% CI 23 to 89) (p<0.0001) as reported in Figure 2.   
 
Figure 3 shows the means of systolic (left panel) and diastolic (right panel) blood pressure by 
presence of knee osteoarthritis at the baseline during the follow-up period. The presence of knee 
osteoarthritis at the baseline was associated with higher blood pressure mean values for systolic 
(p=0.04), but not for diastolic blood pressure (p=0.97).  
 
On multivariate analysis, significant predictors of incident hypertension were: knee osteoarthritis 
which increased the chances of incident hypertension by 13% (HR=1.13; 95% CI: 1.01 to 1.26, 
p=0.03), age (for each year, HR=1.02; 95% CI: 1.001 to 1.02, p<0.01), female gender (HR=1.15; 
95% CI: 1.03 to 1.28, p=0.02), non-white ethnicity (HR=1.53; 95% CI: 1.34 to 1.75, p<0.01), BMI 
(one point corresponded to an increase in incident hypertension of 2% HR: 1.02; 95% CI: 1.01 to 
1.03; p=0.002), and systolic blood pressure at the baseline (each mmHg increases the risk of 
hypertension at follow-up of 4%; HR=1.04; 95% CI: 1.03 to 1.05, p<0.01). Using a propensity score 
the association between knee osteoarthritis at the baseline and incident hypertension remained evident 
(HR=1.11; 95% CI: 1.01 to 1.24; p=0.05).   
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DISCUSSION 
In this large prospective study, our data suggests that the presence of knee osteoarthritis is associated 
with a small but significant increased chance of developing hypertension over an 8-year follow-up. 
Specifically, after adjusting for potential confounders (including baseline blood pressure values at the 
baseline), knee osteoarthritis was associated with a 13% greater chance of developing hypertension.  
 
In this cohort, knee osteoarthritis was a significant predictor for developing hypertension at follow-
up. Several mechanisms have been suggested to explain this possible association. [33] Firstly, people 
with knee osteoarthritis without hypertension at baseline may already have pathological 
modifications of ECM leading to reduced blood vessel elasticity of blood vessels and consequently 
to hypertension. These hypotheses are partially confirmed by our finding since the higher incidence 
of hypertension observed in people with knee osteoarthritis at baseline seems to be attributable to 
higher systolic blood pressure values than diastolic, where it is known that systolic blood pressure is 
more dependent on ECM changes than diastolic one. [34] Molecules such as disintegrin and 
metalloproteinase involved in ECM remodeling appear to have a role in the development of 
hypertension. [33] Interestingly, as shown by our survival curves, people with knee OA at baseline 
developed hypertension mostly at the end of the follow-up. Even if we don’t exactly know the reasons, 
we can assume that the pathways mentioned before need time for altering the ECM and so leading to 
hypertension. However, other studies are needed in this sense. Thirdly, although osteoarthritis is not 
considered an inflammatory arthritis, people with osteoarthritis frequently present with a low-chronic 
inflammation grade [35,36] that could a role in the development of CVD and hypertension. [37] 
Finally, although adjusted for potential confounders, the conditions in common between osteoarthritis 
and hypertension (such as age, obesity, diabetes, reduced physical activity) may be additional 
explanatory factors. Of particular note is that people with OA usually report lower levels of physical 
activity and are more sedentary that those without [38] and these factors probably play a relevant role 
in the development of hypertension.[39] However, using the propensity score and the analyses 
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adjusted for these potential confounders, our findings did not significantly change, indicating that the 
role of these baseline confounders is probably marginal.   
 
Previous studies investigating the role of osteoarthritis as potential CVD risk factor, reported that 
people with osteoarthritis had a significant higher prevalence of hypertension. [4,8–10] However, the 
nature of these studies did not allow the directionality of this association. We attempted to address 
this limitation in the literature in this study. The data proposes that people with osteoarthritis had a 
higher risk of developing hypertension at the follow-up, indicating that blood pressure should be 
strictly monitored in these subjects. Of note, almost half of the people with knee osteoarthritis at the 
baseline assessment developed hypertension, suggesting the importance of this condition. Improved 
surveillance and management of this condition can have a significant impact on long-term health and 
prevention of diseases such as stroke and cardiovascular disease. 
 
Our findings should be considered within the limitations of our study. The measurement of blood 
pressure was made on one occasion with insufficient data to determine whether some individuals had 
blood pressure controlled through medications. The findings of this study therefore related to new-
onset hypertension or uncontrolled hypertension with or without drug treatment. Second, the 
diagnosis of co-morbidities was self-reported and not verified through a review of the participant’s 
medical notes. Third, we do not have sufficient information regarding the use of blood pressure 
lowering medications which could introduce bias in our findings. It is in fact possible that people 
having normal blood pressure at the baseline is due to the use of medications and vice versa. Finally, 
we did not assess any inflammatory or ECM marker, although inflammation could be associated with 
higher CVD risk.[40] Nonetheless, allowing for these caveats, our study involves a large population 
over a long follow-up period. Moreover, we adjusted our analyses for multiple important 
confounders. 
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In conclusion, our study demonstrated that people with knee osteoarthritis have a greater risk of 
developing hypertension in people with osteoarthritis over an 8-year period. Since some interventions 
aiming to improve osteoarthritis symptoms (e.g. increasing physical activity and weight loss 
reduction) seem to be effective from a cardiac perspective, further studies are needed to better 
understand if to treat osteoarthritis can decrease hypertensive risk in these individuals.  
  
15 
 
ACKNOWLEDGMENTS 
Author Disclosure Statement: none. 
 
Funding source: The OAI is a public-private partnership comprised of five contracts (N01-AR-2-
2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National 
Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the 
OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis 
Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI 
is managed by the Foundation for the National Institutes of Health. This manuscript was prepared 
using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI 
investigators, the NIH, or the private funding partners. The funding sources did not have any role in 
in study design; in the collection, analysis and interpretation of data; in the writing of the report; and 
in the decision to submit the article for publication.  
 
 
 
16 
 
REFERENCES 
1.  Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon J a, 
Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, 
Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-
Collo S, Barrero LH, Bartels DH, Basáñez M-G, Baxter A, Bell ML, Benjamin EJ, Bennett 
D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, 
Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, 
Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, 
Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, 
Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, 
Charlson F, Chen H, Cheng AT-A, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun 
S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro 
KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, 
Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos 
A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, 
Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, 
Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri 
CP, Fèvre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes 
FGR, Franklin R, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, 
Garcia B, Gaspari F, Gillum RF, Gmel G, Gosselin R, Grainger R, Groeger J, Guillemin F, 
Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, 
Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy 
D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, 
Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo J-P, King 
CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lalloo R, Laslett LL, 
Lathlean T, Leasher JL, Lee YY, Leigh J, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, 
17 
 
Liu W, Loane M, Ohno SL, Lyons R, Ma J, Mabweijano J, MacIntyre MF, Malekzadeh R, 
Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, 
Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, 
McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer A-C, Miglioli 
V, Miller M, Miller TR, Mitchell PB, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, 
Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, 
Naidoo K, Nair MN, Naldi L, Narayan KMV, Nelson PK, Nelson RG, Nevitt MC, Newton 
CR, Nolte S, Norman P, Norman R, O’Donnell M, O’Hanlon S, Olives C, Omer SB, Ortblad 
K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, 
Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, 
Polanczyk G V, Polinder S, Pope CA, Popova S, Porrini E, Pourmalek F, Prince M, Pullan 
RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, 
Richardson K, Rivara FP, Roberts T, Robinson C, De Leòn FR, Ronfani L, Room R, 
Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, 
Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, 
Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, 
Stapelberg NJC, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, 
Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, 
Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, 
van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt 
K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, 
Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams SRM, Witt E, Wolfe F, 
Woolf AD, Wulf S, Yeh P-H, Zaidi AKM, Zheng Z-J, Zonies D, Lopez AD, Murray CJL, 
AlMazroa MA, Memish ZA, Basanez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, 
Bernabe E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, 
Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, 
18 
 
Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, 
Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, 
Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, 
Charlson F, Chen H, Cheng AT-A, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun 
S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro 
KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, 
Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos 
A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Basáñez M-G, Baxter A, Bell 
ML, Benjamin EJ, Bennett D, Bernabé E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, 
Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, 
Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha 
TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, 
Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, 
Charlson F, Chen H, Cheng AT-A, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun 
S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro 
KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, 
Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos 
A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, 
Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, 
Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri 
CP, Fèvre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes 
FGR, Franklin R, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, 
Garcia B, Gaspari F, Gillum RF, Gmel G, Gosselin R, Grainger R, Groeger J, Guillemin F, 
Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, 
Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotez PJ, Hoy 
D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, 
19 
 
Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo J-P, King 
CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lalloo R, Laslett LL, 
Lathlean T, Leasher JL, Lee YY, Leigh J, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, 
Liu W, Loane M, Ohno SL, Lyons R, Ma J, Mabweijano J, MacIntyre MF, Malekzadeh R, 
Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, 
Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, 
McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer A-C, Miglioli 
V, Miller M, Miller TR, Mitchell PB, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, 
Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, 
Naidoo K, Nair MN, Naldi L, Narayan KMV, Nelson PK, Nelson RG, Nevitt MC, Newton 
CR, Nolte S, Norman P, Norman R, O’Donnell M, O’Hanlon S, Olives C, Omer SB, Ortblad 
K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, 
Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, 
Polanczyk G V, Polinder S, Pope CA, Popova S, Porrini E, Pourmalek F, Prince M, Pullan 
RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, 
Richardson K, Rivara FP, Roberts T, Robinson C, De Leòn FR, Ronfani L, Room R, 
Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, 
Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, 
Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, 
Stapelberg NJC, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, 
Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, 
Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, 
van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt 
K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, 
Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams SRM, Witt E, Wolfe F, 
Woolf AD, Wulf S, Yeh P-H, Zaidi AKM, Zheng Z-J, Zonies D, Lopez AD, Murray CJL, 
20 
 
AlMazroa MA, Memish ZA. Years lived with disability (YLDs) for 1160 sequelae of 289 
diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease 
Study 2010. Lancet [Internet]. 2013 Dec 15 [cited 2014 Jul 10];380(9859):2163–96. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/23245607 
2.  Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, Bridgett L, Williams S, 
Guillemin F, Hill CL, Laslett LL, Jones G, Cicuttini F, Osborne R, Vos T, Buchbinder R, 
Woolf A, March L. The global burden of hip and knee osteoarthritis: estimates from the 
Global Burden of Disease 2010 study. Ann Rheum Dis [Internet]. 2014 Feb 19 [cited 2015 
Oct 21];73(7):1323–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24553908 
3.  Hiligsmann M, Cooper C, Arden N, Boers M, Branco JC, Luisa Brandi M, Bruyère O, 
Guillemin F, Hochberg MC, Hunter DJ, Kanis JA, Kvien TK, Laslop A, Pelletier J-P, Pinto 
D, Reiter-Niesert S, Rizzoli R, Rovati LC, Severens JLH, Silverman S, Tsouderos Y, 
Tugwell P, Reginster J-Y. Health economics in the field of osteoarthritis: an expert’s 
consensus paper from the European Society for Clinical and Economic Aspects of 
Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum [Internet]. 2013 Dec [cited 
2015 Nov 11];43(3):303–13. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23992801 
4.  Hall AJ, Stubbs B, Mamas MA, Myint PK, Smith TO. Association between osteoarthritis and 
cardiovascular disease: Systematic review and meta-analysis. Eur J Prev Cardiol [Internet]. 
2016 Oct 13 [cited 2015 Nov 3];23(9):938–46. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26464295 
5.  Stubbs B, Hurley M, Smith T. What are the factors that influence physical activity 
participation in adults with knee and hip osteoarthritis? A systematic review of physical 
activity correlates. Clin Rehabil [Internet]. 2015 Jan [cited 2015 Nov 4];29(1):80–94. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24917590 
6.  Stubbs B, Aluko Y, Myint PK, Smith TO. Prevalence of depressive symptoms and anxiety in 
21 
 
osteoarthritis: a systematic review and meta-analysis. Age Ageing [Internet]. 2016 Jan 20 
[cited 2016 Feb 2]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/26795974 
7.  Louati K, Vidal C, Berenbaum F, Sellam J. Association between diabetes mellitus and 
osteoarthritis: systematic literature review and meta-analysis. RMD Open  [Internet]. 2015 
Jun 1;1(1). Available from: http://rmdopen.bmj.com/content/1/1/e000077.abstract 
8.  Nüesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Jüni P. All cause and disease specific 
mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 
[Internet]. 2011 Jan [cited 2015 Nov 3];342(mar08_2):d1165. Available from: 
http://www.bmj.com/content/342/bmj.d1165.full.pdf+html 
9.  Veronese N, Trevisan C, De Rui M, Bolzetta F, Maggi S, Zambon S, Musacchio E, Sartori L, 
Perissinotto E, Crepaldi G, Manzato E, Sergi G. Association of Osteoarthritis With Increased 
Risk of Cardiovascular Diseases in the Elderly: Findings From the Progetto Veneto Anziano 
Study Cohort. Arthritis Rheumatol (Hoboken, NJ). 2016 May;68(5):1136–44.  
10.  Rahman MM, Kopec JA, Cibere J, Goldsmith CH, Anis AH. The relationship between 
osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional 
study. BMJ Open. 2013;3(5):10.1136/bmjopen-2013-002624.  
11.  Correction Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, Vollset SE, Ozgoren 
AA, Abdalla S, Abd-Allah F, Aziz MIA, Abera SF, Aboyans V, Abraham B, Abraham JP, 
Abuabara KE, Abubakar I, Abu-Raddad LJ, Abu-Rmeileh NME, Achoki T, Adelekan A, 
Ademi Z, Adofo K, Adou AK, Adsuar JC, ??rnl??v J, Agardh EE, Akena D, Al Khabouri 
MJ, Alasfoor D, Albittar M, Alegretti MA, Aleman A V., Alemu ZA, Alfonso-Cristancho R, 
Alhabib S, Ali MK, Ali R, Alla F, Al Lami F, Allebeck P, AlMazroa MA, Al-Shahi Salman 
R, Alsharif U, Alvarez E, Alviz-Guzman N, Amankwaa AA, Amare AT, Ameli O, Amini H, 
Ammar W, Anderson HR, Anderson BO, Antonio CAT, Anwari P, Apfel H, Cunningham 
SA, Arsenijevic VSA, Artaman A, Asad MM, Asghar RJ, Assadi R, Atkins LS, Atkinson C, 
Badawi A, Bahit MC, Bakfalouni T, Balakrishnan K, Balalla S, Banerjee A, Barber RM, 
22 
 
Barker-Collo SL, Barquera S, Barregard L, Barrero LH, Barrientos-Gutierrez T, Basu A, 
Basu S, Basulaiman MO, Beardsley J, Bedi N, Beghi E, Bekele T, Bell ML, Benjet C, 
Bennett DA, Bensenor IM, Benzian H, Bertozzi-Villa A, Beyene TJ, Bhala N, Bhalla A, 
Bhutta ZA, Bikbov B, Abdulhak A Bin, Biryukov S, Blore JD, Blyth FM, Bohensky MA, 
Borges G, Bose D, Boufous S, Bourne RR, Boyers LN, Brainin M, Brauer M, Brayne CEG, 
Brazinova A, Breitborde N, Brenner H, Briggs ADM, Brown JC, Brugha TS, Buckle GC, 
Bui LN, Bukhman G, Burch M, Campos Nonato IR, Carabin H, C??rdenas R, Carapetis J, 
Carpenter DO, Caso V, Castanda-Orjuela CA, Castro RE, Catal??-L??pez F, Cavalleri F, 
Chang JC, Charlson FC, Che X, Chen H, Chen Y, Chen JS, Chen Z, Chiang PPC, Chimed-
Ochir O, Chowdhury R, Christensen H, Christophi CA, Chuang TW, Chugh SS, Cirillo M, 
Coates MM, Coffeng LE, Coggeshall MS, Cohen A, Colistro V, Colquhoun SM, Colomar 
M, Cooper LT, Cooper C, Coppola LM, Cortinovis M, Courville K, Cowie BC, Criqui MH, 
Crump JA, Cuevas-Nasu L, Da Costa Leite I, Dabhadkar KC, Dandona L, Dandona R, 
Dansereau E, Dargan PI, Dayama A, De la Cruz-G??ngora V, De La Vega SF, De Leo D, 
Degenhardt L, Del Pozo-Cruz B, Dellavalle RP, Deribe K, Des Jarlais DC, Dessalegn M, 
DeVeber GA, Dharmaratne SD, Dherani M, Diaz-Ortega JL, Diaz-Torne C, Dicker D, Ding 
EL, Dokova K, Dorsey ER, Driscoll TR, Duan L, Duber HC, Durrani AM, Ebel BE, Edmond 
KM, Ellenbogen RG, Elshrek Y, Ermakov SP, Erskine HE, Eshrati B, Esteghamati A, Estep 
K, F??rst T, Fahimi S, Fahrion AS, Faraon EJA, Farzadfar F, Fay DFJ, Feigl AB, Feigin VL, 
Felicio MM, Fereshtehnejad SM, Fernandes JG, Ferrari AJ, Fleming TD, Foigt N, Foreman 
K, Forouzanfar MH, Fowkes FGR, Paleo UF, Franklin RC, Futran ND, Gaffikin L, 
Gambashidze K, Gankp?? FG, Garc-Guerra FA, Garcia AC, Geleijnse JM, Gessner BD, 
Gibney KB, Gillum RF, Gilmour S, Ginawi IAM, Giroud M, Glaser EL, Goenka S, Dantes 
HG, Gona P, Gonzalez-Medina D, Guinovart C, Gupta RRRR, Gupta RRRR, Gosselin RA, 
Gotay CC, Goto A, Gouda HN, Graetz N, Greenwell KF, Gugnani HC, Gunnell D, 
Gutii??rez RA, Haagsma J, Hafezi-Nejad N, Hagan H, Hagstromer M, Halasa YA, Hamadeh 
23 
 
RR, Hamavid H, Hammami M, Hancock J, Hankey GJ, Hansen GM, Harb HL, Harewood H, 
Haro JM, Havmoeller R, Hay RJ, Hay SI, Hedayati MT, Pi IBH, Heuton KR, Heydarpour P, 
Higashi H, Hijar M, Hoek HW, Hoffman HJ, Hornberger JC, Hosgood HD, Hossain M, 
Hotez PJ, Hoy DG, Hsairi M, Hu G, Huang JJ, Huffman MD, Hughes AJ, Husseini A, 
Huynh C, Iannarone M, Iburg KM, Idrisov BT, Ikeda N, Innos K, Inoue M, Islami F, 
Ismayilova S, Jacobsen KH, Jassal S, Jayaraman SP, Jensen PN, Jha V, Jiang G, Jiang Y, 
Jonas JB, Joseph J, Juel K, Kabagambe EK, Kan H, Karch A, Karimkhani C, Karthikeyan G, 
Kassebaum N, Kaul A, Kawakami N, Kazanjan K, Kazi DS, Kemp AH, Kengne AP, Keren 
A, Kereselidze M, Khader YS, Ali Hassan Khalifa SE, Khan EA, Khan G, Khang YH, 
Kieling C, Kinfu Y, Kinge JM, Kim D, Kim S, Kivipelto M, Knibbs L, Knudsen AK, 
Kokubo Y, Kosen S, Kotagal M, Kravchenko MA, Krishnaswami S, Krueger H, Defo BK, 
Kuipers EJ, Kucuk Bicer B, Kulkarni C, Kulkarni VS, Kumar K, Kumar RB, Kwan GF, Kyu 
H, Lai T, Balaji AL, Lalloo R, Lallukka T, Lam H, Lan Q, Lansingh VC, Larson HJ, Larsson 
A, Lavados PM, Lawrynowicz AEB, Leasher JL, Lee JT, Leigh J, Leinsalu M, Leung R, 
Levitz C, Li B, Li YY, Li YY, Liddell C, Lim SS, De Lima GMF, Lind ML, Lipshultz SE, 
Liu S, Liu Y, Lloyd BK, Lofgren KT, Logroscino G, London SJ, Lortet-Tieulent J, Lotufo 
PA, Lucas RM, Lunevicius R, Lyons RA, Ma S, Pedro Machado VM, MacIntyre MF, 
Mackay MT, MacLachlan JH, Magis-Rodriguez C, Mahdi AA, Majdan M, Malekzadeh R, 
Mangalam S, Mapoma CC, Marape M, Marcenes W, Margono C, Marks GB, Marzan MB, 
Masci JR, Mashal MT, Masiye F, Mason-Jones AJ, Matzopolous R, Mayosi BM, Mazorodze 
TT, McGrath JJ, McKay AC, McKee M, McLain A, Meaney PA, Mehndiratta MM, Mejia-
Rodriguez F, Melaku YA, Meltzer M, Memish ZA, Mendoza W, Mensah GA, Meretoja A, 
Mhimbira FA, Miller TR, Mills EJ, Misganaw A, Mishra SK, Mock CN, Moffitt TE, Ibrahim 
NM, Mohammad KA, Mokdad AH, Mola GL, Monasta L, De La Cruz Monis J, Hernandez 
JCM, Montico M, Montine TJ, Mooney MD, Moore AR, Moradi-Lakeh M, Moran AE, Mori 
R, Moschandreas J, Moturi WN, Moyer ML, Mozaffarian D, Mueller UO, Mukaigawara M, 
24 
 
Mullany EC, Murray J, Mustapha A, Naghavi P, Naheed A, Naidoo KS, Naldi L, Nand D, 
Nangia V, Narayan KMV, Nash D, Nasher J, Nejjari C, Nelson RG, Neuhouser M, Neupane 
SP, Newcomb PA, Newman L, Newton CR, Ng M, Ngalesoni FN, Nguyen G, Nguyen NTT, 
Nisar MI, Nolte S, Norheim OF, Norman RE, Norrving B, Nyakarahuka L, Odell S, 
O’Donnell M, Ohkubo T, Ohno SL, Olusanya BO, Omer SB, Opio JN, Orisakwe OE, 
Ortblad KF, Ortiz A, Otayza MLK, Pain AW, Pandian JD, Panelo CI, Panniyammakal J, 
Papachristou C, Paternina Caicedo AJ, Patten SB, Patton GC, Paul VK, Pavlin B, Pearce N, 
Pellegrini CA, Pereira DM, Peresson SC, Perez-Padilla R, Perez-Ruiz FP, Perico N, Pervaiz 
A, Pesudovs K, Peterson CB, Petzold M, Phillips BK, Phillips DE, Phillips MR, Plass D, Piel 
FB, Poenaru D, Polinder S, Popova S, Poulton RG, Pourmalek F, Prabhakaran D, Qato D, 
Quezada AD, Quistberg DA, Rabito F, Rafay A, Rahimi K, Rahimi-Movaghar V, Rahman 
SUR, Raju M, Rakovac I, Rana SM, Refaat A, Remuzzi G, Ribeiro AL, Ricci S, Riccio PM, 
Richardson L, Richardus JH, Roberts B, Roberts DA, Robinson M, Roca A, Rodriguez A, 
Rojas-Rueda D, Ronfani L, Room R, Roth GA, Rothenbacher D, Rothstein DH, Rowley JTF, 
Roy N, Ruhago GM, Rushton L, Sambandam S, S??reide K, Saeedi MY, Saha S, Sahathevan 
R, Sahraian MA, Sahle BW, Salomon JA, Salvo D, Samonte GMJ, Sampson U, Sanabria JR, 
Sandar L, Santos IS, Satpathy M, Sawhney M, Saylan M, Scarborough P, Sch??ttker B, 
Schmidt JC, Schneider IJC, Schumacher AE, Schwebel DC, Scott JG, Sepanlou SG, Servan-
Mori EE, Shackelford K, Shaheen A, Shahraz S, Shakh-Nazarova M, Shangguan S, She J, 
Sheikhbahaei S, Shepard DS, Shibuya K, Shinohara Y, Shishani K, Shiue I, Shivakoti R, 
Shrime MG, Sigfusdottir ID, Silberberg DH, Silva AP, Simard EP, Sindi S, Singh JA, Singh 
L, Sioson E, Skirbekk V, Sliwa K, So S, Soljak M, Soneji S, Soshnikov SS, Sposato LA, 
Sreeramareddy CT, Stanaway JD, Stathopoulou VK, Steenland K, Stein C, Steiner C, 
Stevens A, St??ckl H, Straif K, Stroumpoulis K, Sturua L, Sunguya BF, Swaminathan S, 
Swaroop M, Sykes BL, Tabb KM, Takahashi K, Talongwa RT, Tan F, Tanne D, Tanner M, 
Tavakkoli M, Ao B Te, Teixeira CM, Templin T, Tenkorang EY, Terkawi AS, Thomas BA, 
25 
 
Thorne-Lyman AL, Thrift AG, Thurston GD, Tillmann T, Tirschwell DL, Tleyjeh IM, 
Tonelli M, Topouzis F, Towbin JA, Toyoshima H, Traebert J, Tran BX, Truelsen T, Trujillo 
U, Trillini M, Dimbuene ZT, Tsilimbaris M, Tuzcu EM, Ubeda C, Uchendu US, Ukwaja 
KN, Undurraga EA, Vallely AJ, Van De Vijver S, Van Gool CH, Varakin YY, Vasankari TJ, 
Vasconcelos AMN, Vavilala MS, Venketasubramanian N, Vijayakumar L, Villalpando S, 
Violante FS, Vlassov VV, Wagner GR, Waller SG, Wang JL, Wang L, Wang XR, Wang Y, 
Warouw TS, Weichenthal S, Weiderpass E, Weintraub RG, Wenzhi W, Werdecker A, 
Wessells KRR, Westerman R, Whiteford HA, Wilkinson JD, Williams TN, Woldeyohannes 
SM, Wolfe CDA, Wolock TM, Woolf AD, Wong JQ, Wright JL, Wulf S, Wurtz B, Xu G, 
Yang YC, Yano Y, Yatsuya H, Yip P, Yonemoto N, Yoon SJ, Younis M, Yu C, Jin KY, El 
Sayed Zaki M, Zamakhshary MF, Zeeb H, Zhang Y, Zhao Y, Zheng Y, Zhu J, Zhu S, Zonies 
D, Zou XN, Zunt JR, Vos T, Lopez AD, Murray CJL, Alcal??-Cerra G, Balala S, Chang CC, 
Gosslin RA, Hu H, Karam N, Sabin N, Temesgen AM. Global, regional, and national age-
sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A 
systematic analysis for the Global Burden of Disease Study 2013. Lancet [Internet]. 
2015;385(9963):117–71. Available from: http://dx.doi.org/10.1016/S0140-6736(14)61682-2 
12.  Veronese N, Cereda E, Maggi S, Luchini C, Solmi M, Smith T, Denkinger M, Hurley M, 
Thompson T, Manzato E, Sergi G, Stubbs B. Osteoarthritis and Mortality: A Prospective 
Cohort Study and Systematic Review with Meta-analysis. Semin Arthritis Rheum [Internet]. 
2016 Apr [cited 2016 Apr 15];46(2):160–7. Available from: 
http://www.semarthritisrheumatism.com/article/S0049017216300087/fulltext 
13.  Bonnet CS, Walsh DA. Osteoarthritis, angiogenesis and inflammation. Rheumatology 
[Internet]. 2005 Jan 1 [cited 2016 Apr 23];44(1):7–16. Available from: 
http://rheumatology.oxfordjournals.org/content/44/1/7.short 
14.  Hardingham T. Extracellular matrix and pathogenic mechanisms in osteoarthritis. Vol. 10, 
Current Rheumatology Reports. 2008. p. 30–6.  
26 
 
15.  Velagaleti RS, Gona P, Sundstr??m J, Larson MG, Siwik D, Colucci WS, Benjamin EJ, 
Vasan RS. Relations of biomarkers of extracellular matrix remodeling to incident 
cardiovascular events and mortality. Arterioscler Thromb Vasc Biol. 2010;30(11):2283–8.  
16.  Stubbs B, Binnekade TT, Soundy A, Schofield P, Huijnen IPJ, Eggermont LHP. Are older 
adults with chronic musculoskeletal pain less active than older adults without pain? A 
systematic review and meta-analysis. Pain Med [Internet]. 2013 Sep [cited 2015 Nov 
4];14(9):1316–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23742160 
17.  Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T. Association of knee 
osteoarthritis with the accumulation of metabolic risk factors such as overweight, 
hypertension, dyslipidemia, and impaired glucose tolerance in Japanese men and women: the 
ROAD study. J Rheumatol. 2011 May;38(5):921–30.  
18.  Sohn M-W, Manheim LM, Chang RW, Greenland P, Hochberg MC, Nevitt MC, Semanik 
PA, Dunlop DD. Sedentary behavior and blood pressure control among osteoarthritis 
initiative participants. Osteoarthr Cartil. 2014 Sep;22(9):1234–40.  
19.  Nielen MMJ, van Sijl AM, Peters MJL, Verheij RA, Schellevis FG, Nurmohamed MT. 
Cardiovascular disease prevalence in patients with inflammatory arthritis, diabetes mellitus 
and osteoarthritis: a cross-sectional study in primary care. BMC Musculoskelet Disord. 2012 
Aug;13:150.  
20.  Morovic-Vergles J, Salamon L, Marasovic-Krstulovic D, Kehler T, Sakic D, Badovinac O, 
Vlak T, Novak S, Stiglic-Rogoznica N, Hanih M, Bedekovic D, Grazio S, Kadojic M, Milas-
Ahic J, Prus V, Stamenkovic D, Soso D, Anic B, Babic-Naglic D, Gamulin S. Is the 
prevalence of arterial hypertension in rheumatoid arthritis and osteoarthritis associated with 
disease? Rheumatol Int. 2013 May;33(5):1185–92.  
21.  Miksch A, Hermann K, Rolz A, Joos S, Szecsenyi J, Ose D, Rosemann T. Additional impact 
of concomitant hypertension and osteoarthritis on quality of life among patients with type 2 
diabetes in primary care in Germany - a cross-sectional survey. Health Qual Life Outcomes. 
27 
 
2009 Feb;7:19.  
22.  Liu Y, Zhang H, Liang N, Fan W, Li J, Huang Z, Yin Z, Wu Z, Hu J. Prevalence and 
associated factors of knee osteoarthritis in a rural Chinese adult population: an 
epidemiological survey. BMC Public Health. 2016 Jan;16:94.  
23.  Hochberg MC. New paradigms in the management of osteoarthritis patients with 
hypertension. Vol. 18, Osteoarthritis and cartilage. England; 2010. p. S1-2.  
24.  Bae Y-H, Shin J-S, Lee J, Kim M, Park KB, Cho J-H, Ha I-H. Association between 
Hypertension and the Prevalence of Low Back Pain and Osteoarthritis in Koreans: A Cross-
Sectional Study. PLoS One. 2015;10(9):e0138790.  
25.  Oparil S, Zaman MA, Calhoun DA. Pathogenesis of Hypertension. Vol. 139, Annals of 
Internal Medicine. 2003. p. 761–76.  
26.  Altman RD, Gold GE. Atlas of individual radiographic features in osteoarthritis, revised. 
Osteoarthr Cartil [Internet]. 2016 Nov 18;15:A1–56. Available from: 
http://dx.doi.org/10.1016/j.joca.2006.11.009 
27.  Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of 
WOMAC: a health status instrument for measuring clinically important patient relevant 
outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J 
Rheumatol [Internet]. 1988 Dec [cited 2015 Oct 1];15(12):1833–40. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/3068365 
28.  Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps 
SG, Roccella EJ. Recommendations for blood pressure measurement in humans and 
experimental animals: Part 1: blood pressure measurement in humans: a statement for 
professionals from the Subcommittee of Professional and Public Education of the American 
Heart Association Cou. Hypertension [Internet]. 2005 Jan [cited 2015 Mar 20];45(1):142–61. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/15611362 
29.  Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW. Can comorbidity be measured by 
28 
 
questionnaire rather than medical record review? Med Care [Internet]. 1996 Jan [cited 2016 
Mar 25];34(1):73–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8551813 
30.  Washburn RA, McAuley E, Katula J, Mihalko SL, Boileau RA. The physical activity scale 
for the elderly (PASE): evidence for validity. J Clin Epidemiol [Internet]. 1999 Jul [cited 
2016 Mar 17];52(7):643–51. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/10391658 
31.  Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General 
Population. Appl Psychol Meas [Internet]. 1977 Jun 1 [cited 2014 Jul 9];1(3):385–401. 
Available from: http://conservancy.umn.edu/handle/11299/98561 
32.  Yanovitzky I, Zanutto E, Hornik R. Estimating causal effects of public health education 
campaigns using propensity score methodology. Eval Program Plann. 2005;28(2):209–20.  
33.  Fernandes GS, Valdes AM. Cardiovascular Disease and Osteoarthritis: Common Pathways 
and Patient Outcomes. Eur J Clin Invest [Internet]. 2015;45:n/a-n/a. Available from: 
http://doi.wiley.com/10.1111/eci.12413 
34.  Xu J, Shi G-P. Vascular wall extracellular matrix proteins and vascular diseases. Biochim 
Biophys Acta [Internet]. 2014;1842(11):2106–19. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25045854 
35.  Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). 
Vol. 21, Osteoarthritis and Cartilage. 2013. p. 16–21.  
36.  Berenbaum F, Eymard F, Houard X. Osteoarthritis, inflammation and obesity. Curr Opin 
Rheumatol. 2013;25(1):114–8.  
37.  Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys 
MB. Low grade inflammation and coronary heart disease: prospective study and updated 
meta-analyses. BMJ [Internet]. 2000;321(7255):199–204. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=27435&tool=pmcentrez&rendert
ype=abstract 
29 
 
38.  Wallis JA, Webster KE, Levinger P, Taylor NF. What proportion of people with hip and 
knee osteoarthritis meet physical activity guidelines? A systematic review and meta-analysis. 
Osteoarthritis Cartilage [Internet]. 2013 Nov [cited 2015 Oct 28];21(11):1648–59. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/23948979 
39.  Booth FW, Roberts CK, Laye MJ. Lack of exercise is a major cause of chronic diseases. 
Compr Physiol [Internet]. 2012 Apr [cited 2015 Jun 15];2(2):1143–211. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4241367&tool=pmcentrez&rend
ertype=abstract 
40.  Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 
2006;83(2):456S–460S.  
 
30 
 
Table 1. Baseline characteristics classified according to presence or not of knee osteoarthritis 
(osteoarthritis). 
Numbers are mean values (and standard deviations) or number (and percentages), as appropriate. 
 
*Unless otherwise specified, p values are calculated with an independent Student T-test for 
continuous and with a chi-square test for categorical variables, respectively.  
 
Abbreviations: BMI: body mass index; COPD: chronic obstructive pulmonary disease.; CESD: 
Center for Epidemiologic Studies-Depression; PASE: physical activity scale for the elderly. 
Variable Knee 
osteoarthritis 
 (n=1,930) 
No 
osteoarthritis 
(n=1,628) 
p value* 
Age (years) 61.8 (9.1) 58.9 (8.8) <0.0001 
Females (n, %) 1125 (58.3) 993 (61.0) 0.11 
White race (n, %) 1574 (81.6) 1340 (82.5) 0.48 
BMI (kg/m2) 29.2 (4.8) 27.1 (4.5) <0.0001 
Smoking (previous/current) (n, %) 732 (45.4) 878 (46.0) 0.73 
College and above (n, %) 598 (36.9) 552 (28.8) <0.0001 
Yearly income (<50,000 $) 719 (37.3) 504 (31.0) <0.0001 
PASE score (points) 158.4 (80.7) 170.0 (84.0) <0.0001 
Medical conditions    
Diabetes (n, %) 167 (8.8) 78 (4.9) <0.0001 
COPD (n, %) 38 (2.0) 34 (2.1) 0.81 
Cardiovascular diseases (n, %) 131 (7.0) 88 (5.5) 0.08 
Cancer (n, %) 101 (5.2) 72 (4.4) 0.27 
Charlson co-morbidity score (points) 0.4 (0.9) 0.3 (0.8) 0.01 
    
CESD (points) 6.4 (6.7) 6.5 (6.5) 0.93 
Systolic blood pressure (mmHg) 119.4 (10.8) 117.1 (11.3) <0.0001 
Diastolic blood pressure (mmHg) 73.4 (8.1) 72.7 (8.6) 0.02 
31 
 
Figure 1. Cohort flow-chart.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Patients enrolled in the Osteoarthritis Initiative Project: 4796 
Patients included in the present study: 3558 
No information 
regarding knee 
OSTEOARTHRITIS: 33 
High blood pressure at 
baseline: 1005 
Lost at follow-
up/deceased: 200 
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Figure 2. Risk of hypertension by presence of knee osteoarthritis at the baseline.  
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Figure 3. Mean systolic (left) and diastolic (right) blood pressure values by the presence of knee 
osteoarthritis at the baseline.  
 
 
 
 
 
 
Notes: the red line represent the people having knee osteoarthritis at the baseline; the blue those 
without.  
 
 
 
 
